PRPO

EX-99.1

2 tm2623274d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

Precipio Announces Q2-2026 Financial Results

Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position

NEW HAVEN, CT, Globenewswire – (Aug 14, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces financial results for the second quarter that ended June 30, 2026.

Below are some of the key financial performance metrics for the Company. For additional results please see the Company’s Form 10-Q which was filed today.

●Revenue – $7.0M vs. $6.7M in Q1-2026, and up 22% YoY from $5.7M in Q2-2025. This comprised of $6.1M in pathology revenue (up from $6.0M in Q1) and $0.9M in product revenue (up from $0.66M in Q1).

●Adjusted EBITDA – $0.4M vs. $(0.2)M in Q1-2026. The change was driven by increased revenues of $0.3 million and a decrease in stock-based compensation expense of $0.2M.

●Cash flow - Cash Flow generated from operations was $0.7M in Q2-2026; total increase in cash was $0.5 million, resulting in an end of quarter cash balance exceeding $3M, vs $1.1M in Q2-2025.

“As anticipated, Q2 operating performance reflects a healthy recovery and continued momentum across the business, with customer growth generating quarterly revenue surpassing $7M for the first time in Company history. Product revenues increased 21% from the previous high of $750K in Q4-2025, and cash increased to over $3M.” said Ilan Danieli, CEO of Precipio. “We’ve achieved this level of cash without a financing event, demonstrating the strength of our operations. We're encouraged by the progress we've made and believe we are well positioned to continue building on this momentum.”

Additional information and a more in-depth discussion on the Company’s Q2-2026 performance will be provided in the shareholder call on August 17th, 2026, at 5 PM ET. The call will include remarks by management on the Company’s core business, followed by a moderated Q&A session.

EBITDA and Adjusted EBITDA Reconciliation and Explanation

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-GAAP financial measure that is widely used to evaluate operational performance and pre-tax profitability of emerging growth companies like ours. Management believes Adjusted EBITDA provides investors with a useful perspective on the Company’s financial health, particularly where non-cash amortization has an important impact on profitability.

Adjusted EBITDA as we define it modifies EBITDA by excluding the non-cash costs of employee stock options and unusual non-operating income and expense. Below is a reconciliation of Net Income, EBITDA and Adjusted EBITDA for the second quarter of 2026 and 2025:

($ in millions, unaudited)

Q2-26

Q2-25

Net income/(loss) (GAAP) $(0.2) $0.1

Adjustments to net income/(loss):

Interest expense, net $0.0 $0.0

Income taxes $0.0 $0.0

Depreciation $0.0 $0.1

Amortization of intangibles $0.2 $0.2

EBITDA (non-GAAP) $0.0 $0.4

Further Adjustments to EBITDA

Stock-based compensation expense

$0.8 $0.4

Other significant (income) expenses $(0.4) $(0.9)

Adjusted EBITDA (non-GAAP) $0.4 $(0.1)

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.

Availability of Other Information About Precipio

For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” wi

false 0001043961

0001043961

2026-02-25 2026-02-25

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE

ACT OF 1934

Date of report (Date of earliest event reported): February 25, 2026

PRECIPIO,

INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-36439

91-1789357

(State of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

4 Science Park, New Haven,

CT 06511

(Address of principal executive offices) (Zip Code)

(203) 787-7888

(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report date)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Ticker symbol(s) Name of each exchange on which

registered

Common Stock, $0.01 par value per share

PRPO

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

On February 25, 2026, Precipio, Inc. (the “Company”) announced its preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release issued by Precipio Inc. on February 25, 2026, furnished herewith.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRECIPIO, INC.

By: /s/ Ilan Danieli

Name: Ilan Danieli

Title: Chief Executive Officer

Date: February 27, 2026

false 0001043961

0001043961

2025-05-14 2025-05-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE

ACT OF 1934

Date of report (Date of earliest event reported): May 14, 2025

PRECIPIO,

INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-36439

91-1789357

(State of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

4 Science Park, New Haven,

CT 06511

(Address of principal executive offices) (Zip Code)

(203) 787-7888

(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report date)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Ticker symbol(s) Name of each exchange on which

registered

Common Stock, $0.01 par value per share

PRPO

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

On May 14, 2025, Precipio, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release issued by Precipio Inc. on May 14, 2025, furnished herewith.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRECIPIO, INC.

By: /s/ Ilan Danieli

Name: Ilan Danieli

Title: Chief Executive Officer

Date: May 15, 2025